Gai-Li Chen

Gai-Li Chen

Auto-generated profile, based on publicly available information

Gai-Li Chen

Department of Radiation and Medical Oncology, Hubei Key Laboratory of Tumor Biological Behaviors, Hubei Cancer Clinical Study Center, Zhongnan Hospital of Wuhan University, Wuhan, China

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 June 2020 in Psycho-Oncology
Verified
Journal Article
Closed access
PDF file
GCGaili Chen
Gaili Chen
QWQiuji Wu
Qiuji Wu
HJHuangang Jiang
Huangang Jiang
HZHongyan Zhang
Hongyan Zhang
JPJin Peng
Jin Peng
CXConghua Xie
Conghua Xie

8 December 2022 in Cancer Immunology Research
Verified
Journal Article
Closed access
PDF file
BXBo-Lin Xiao
Bo-Lin Xiao
XWXiao-Le Wang
Xiao-Le Wang
HXHou-Fu Xia
Hou-Fu Xia
LZLin-Zhou Zhang
Lin-Zhou Zhang
KWKui-ming Wang
Kui-ming Wang
GCGang Chen
Gang Chen
PD-L1 localized to immunosuppressive small extracellular vesicles (sEV PD-L1) contributes to tumor progression and is associated with resistance to immune-checkpoint blockade (ICB) therapy. Here, by establishing a screening strategy with a combination of tissue microarray (TMA), IHC staining, and measurement of circulating sEV PD-L1, we found that the endosomal sorting complex required for transport (ESCRT) member protein hepatocyte growth factor–regulated tyrosine kinase substrate (HRS) was the key regulator of circulating sEV PD-L1 in head and neck squamous cell carcinoma (HNSCC) patients. Increased HRS expression was found in tumor tissues and positively correlated with elevated circulating sEV PD-L1 in patients with HNSCC. The expression of HRS was also negatively correlated to the infiltration of CD8+ T cells. Knockdown of HRS markedly reduced PD-L1 expression in HNSCC cell–derived sEVs, and these sEVs from HRS knockdown cells showed decreased immunosuppressive effects on CD8+ T cells. Knockout of HRS inhibited tumor growth in immunocompetent mice together with PD-1 blockade. Moreover, a higher HRS expression was associated with a lower response rate to anti–PD-1 therapy in patients with HNSCC. In summary, our study reveals HRS, the core component of ESCRT-0, regulates sEV PD-L1 secretion, and is associated with the response to ICB therapy in patients with HNSCC, suggesting HRS is a promising target to improve cancer immunotherapy.

10 December 2020 in Head & Neck
Verified
Journal Article
Closed access
PDF file
GCGaili Chen
Gaili Chen
HJHuangang Jiang
Huangang Jiang
DJDazhen Jiang
Dazhen Jiang
QWQiuji Wu
Qiuji Wu
ZLZheng Li
Zheng Li
YZYahua ZHONG
Yahua ZHONG

26 November 2025
Verified
Other
Open access
BXBo-Lin Xiao
Bo-Lin Xiao
XWXiao-Le Wang
Xiao-Le Wang
HXHou-Fu Xia
Hou-Fu Xia
LZLin-Zhou Zhang
Lin-Zhou Zhang
KWKui-ming Wang
Kui-ming Wang
GCGang Chen
Gang Chen
PD-L1 localized to immunosuppressive small extracellular vesicles (sEV PD-L1) contributes to tumor progression and is associated with resistance to immune-checkpoint blockade (ICB) therapy. Here, by establishing a screening strategy with a combination of tissue microarray (TMA), IHC staining, and measurement of circulating sEV PD-L1, we found that the endosomal sorting complex required for transport (ESCRT) member protein hepatocyte growth factor–regulated tyrosine kinase substrate (HRS) was the key regulator of circulating sEV PD-L1 in head and neck squamous cell carcinoma (HNSCC) patients. Increased HRS expression was found in tumor tissues and positively correlated with elevated circulating sEV PD-L1 in patients with HNSCC. The expression of HRS was also negatively correlated to the infiltration of CD8+ T cells. Knockdown of HRS markedly reduced PD-L1 expression in HNSCC cell–derived sEVs, and these sEVs from HRS knockdown cells showed decreased immunosuppressive effects on CD8+ T cells. Knockout of HRS inhibited tumor growth in immunocompetent mice together with PD-1 blockade. Moreover, a higher HRS expression was associated with a lower response rate to anti–PD-1 therapy in patients with HNSCC. In summary, our study reveals HRS, the core component of ESCRT-0, regulates sEV PD-L1 secretion, and is associated with the response to ICB therapy in patients with HNSCC, suggesting HRS is a promising target to improve cancer immunotherapy.